From Yahoo Finance: 2025-05-17 13:36:00

Oppenheimer raised Acadia Pharmaceuticals’ price target to $19 from $17, maintaining a Perform rating. The Delaware court ruled in favor of Acadia, affirming Nuplazid’s intellectual property protection and removing a perceived overhang on the shares. The court found Aurobindo infringed on patent claims. Investor focus expected to shift to key dynamics post Q1 update and ahead of R&D day on June 25.



Read more at Yahoo Finance: Acadia Pharmaceuticals price target raised to $19 from $17 at Oppenheimer